This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

2013 FDA Drug Approval Calendar

BOSTON ( TheStreet) -- Gilead Sciences (GILD) and Amarin (AMRN) highlight the updated list of biotech and pharmaceutical companies with FDA drug approval decisions expected for the remainder of 2013.

The next era of hepatitis C therapy could begin on Dec. 6, if FDA approves Gilead's sofosbuvir. Amarin is hoping FDA approves an expanded label for its prescription-grade fish oil pill Vascepa on Dec. 20.

Sarepta Therapeutics (SRPT) and Pharmacyclics (PCYC) aren't on the list but are still very much in the investor spotlight. Sarepta and FDA are still going back and forth over the the company's request to file an accelerated approval application for eteplirsen to treat Duchenne muscular dystrophy. We may have some resolution early in the third quarter.

Pharmacylics and partner Johnson & Johnson (JNJ) are expected to seek FDA approval for their blood-cancer drug ibrutinib before the end of the third quarter. FDA has already annointed ibrutinib with multiple breakthrough therapy designations, so it makes sense for the agency to approve the drug quickly. Is an ibrutinib approval before year end a possibility? I think so, in fact, I'd say the Street expects an early approval.

Let's not forget the importance of European drug approvals. Here are the dates for the remaining Committee for Medicinal Products for Human Use (CHMP) meetings in 2013:

May 27-30; June 24-27; July 22-25; Aug. 19-22; Sept. 16-19; Oct. 21-24; Nov. 18-2; and Dec. 16-19.

The most closely watched, upcoming European drug approval decisions include Dendreon (DNDN) (Provenge, prostate cancer); Aegerion Pharmaceuticals (AEGR) (Juxtapid, homozygous familial hypercholesterolemia) and Celgene (CELG) (Pomalyst, multiple myeloma.)

Biotech and drug stocks below are listed in chronological order based on the closest regulatory catalyst -- FDA drug approval decisions and advisory panels.

Merck (MRK)
Drug/indication: Suvorexant for insomnia
FDA advisory panel: May 22
Approval decision date: June-July

Valeant Pharmaceuticals (VRX)
Drug/indication: Efinaconazole, toe-nail fungus
Approval decision date: May 23

Depomed (DEPO)
Drug/indication: Sefelsa, menopause
Approval decision date: May 31

Zogenix (ZGNX)
Drug/indication: Zohydro, chronic pain
Approval decision date: Summer

GlaxoSmithKline (GSK)
Drug/indication: Dabrafenib, melanoma
Approval decision date: June 3

Aveo Pharmaceuticals (AVEO)
Drug/indication: Tivozanib, kidney cancer
Approval decision date: July 26

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,031.14 +43.63 0.26%
S&P 500 1,984.13 -1.41 -0.07%
NASDAQ 4,518.9020 -48.6960 -1.07%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs